

## Amundi Bonus Builder Fund

Amundi Alternative Investments

MICA (P) 076/08/2010

### Investment Policy

Amundi Bonus Builder Fund (the "Fund") seeks to provide investors with (i) a fixed payout of 4.8% per annum of the Initial Offer Price per Unit, comprising 4 quarterly payouts of 1.2% of the Initial Offer Price per Unit payable on the last Dealing Day at the end of each calendar quarter; (ii) 80% lock-in of the highest Net Asset Value per Unit of the Fund observed over the past 12 months on a rolling basis (Minimum Floor), and (iii) long-term capital growth through participation in Asian (including Japan) and Australian equity indices.

### Important Information

Investors should note that with effect from 8 December 2009, the Fund shall be terminated by the Manager without obtaining any further approval, by giving at least three months' prior written notice to unit holders, should the Net Asset Value per Unit of the Fund fall below 50% of the Initial Offer Price per Unit determined at the time of the establishment of the Fund for its Initial Offer Period (i.e. below S\$0.50 per Unit as the Initial Offer Price per Unit was S\$1.00) at any time during the life of the Fund. Please refer to the prospectus for further details.

### Fund Manager's Commentary

The financial market continues to be volatile in November. Europe was more or less the center of the turmoil. Political uncertainties played the major roll on the instabilities in the markets. Greek called for a referendum over the acceptance of the bailout package, which then was called off. These events contributed to the early month drops on the equities market. The yield on Italian government bonds surged and 10 yr yield stayed most of November around 7%.

US economic data shows some positive signs but signals that economic fundamentals are still fragile. The fiscal super committee announced 21 Nov, that it would not reach agreement, adding the uncertainty on the US fiscal policy.

As of the end of November, the fund was exposed at 14.3% to equity indices through financial derivatives instruments: 2.9% to Hong Kong, 3.1% to Korean market, 3.1% to Australian market, 2.7% to TOPIX and 2.6% to Taiwanese market.

Unless otherwise stated, all performances are in SGD terms, bid-to-bid.

### Fund Details


NAV (as of 30 Nov 11)	: SGD 0.707
Fund size (as of 30 Nov 11)	: SGD 31.0 million
Inception date	: 8 December 2005
Guarantor	: Societe Generale S.A.
Fund currency	: SGD
Minimum initial subscription	: SGD 1,000
Preliminary charge	: Currently 3%, Max 5%
Realisation charge	: Currently Nil, Up to 1.00%
Total management fee	: 1.50% p.a., Max 2.00% p.a.
Bloomberg code	: SGBBUIL SP
ISIN code	: SG9999004568

### Amundi Singapore Limited

Company Registration No. 198900774E  
168 Robinson Road, #24-01 Capital Tower  
Singapore 068912  
Tel: (65) 6536 4822 Fax: (65) 6536 4322  
www.amundi.com/sgp

### Performance from 8 December 2005 - 30 November 2011

November 2011



	1 month	3 months	1 Year	3 Years annualized	5 Years annualized	Inception annualized
Fund (SGD, offer-to-bid)	-3.8%	-4.4%	-6.2%	-2.2%	-2.4%	-0.9%
Fund (SGD, bid-to-bid)	-1.0%	-1.6%	-3.5%	-1.2%	-1.8%	-0.4%

Source: Amundi Singapore Limited. Returns are computed up to 30 November 2011 and on the assumption that all dividends and distributions are reinvested, taking into account all charges which would have been payable upon such reinvestment. More current performance may be lower than the above stated performance.

### Payout information\*

History (calculated as % of initial offer price of SGD 1.000)

YTD 2011	3.60%
Quarterly payouts in 2010	Total of 4.80%
Quarterly payouts in 2009	Total of 4.80%
Quarterly payouts in 2008	Total of 4.80%
Quarterly payouts in 2007	Total of 4.80%
Quarterly payouts in 2006	Total of 4.80%
Decmeber 2005	1.20%

\* Payout from the Fund may be made out of the capital of the Fund.

### Minimum floor calculation

Minimum Floor as of 30 November 2011 is SGD 0.6424 (equals 80% of highest NAV per unit attained over the last twelve months, i.e. SGD 0.803 x 80%)

Source: Amundi Singapore Limited, as of 30 November 2011

**Important Information: Please note that this is not a 100% Capital Guaranteed Fund.** Investors should note that only the Payouts and Minimum Floor are backed by a Guarantee (as defined in the prospectus) provided by the Guarantor, and is subject to the issuer risk. The guarantee on the Payouts only applies to investors who hold their investment until the relevant Payout Date. This document is provided for information purposes only and does not constitute an offer or solicitation to purchase or sell units in the Fund. The prospectus is available and may be obtained from the Manager or its authorised distributors. Investors should read the relevant prospectus before deciding to invest in the Fund. All applications must be made on application forms accompanying the prospectus. Past performance and any forecasts made are not indicative of future performance. Any opinion or view presented is subject to change without notice. The information on this factsheet is intended for general circulation without taking into account the specific investment objectives, financial situation or particular needs of any particular investor. An investor may wish to seek advice from a financial adviser regarding the suitability of the Fund before making a commitment to purchase units in the Fund. In the event an investor chooses not to do so, the investor should consider whether the Fund is suitable for him. Investments in the Fund is subject to investment risks, including the possible loss of the principal amount invested. Value of the units in the Fund and the income accruing to the units, if any, may fall or rise. Some of the information contained herein has been obtained from sources believed to be reliable but has not been independently verified, although Amundi Singapore Limited and its affiliated companies believe it to be fair and not misleading. As the Fund may invest in financial derivatives as part of the investment strategy, it will be subject to risks associated with such investments. Additional risk factors are described in the prospectus.